23 Apr Fuzuloparib as Maintenance Therapy is Effective Regardless of BRCA 1/2 Mutation
Posted at 10:42h in Blogs 0 Comments
In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared with placebo, regardless of germline BRCA 1/2 mutation. (Ref: Li N et al. J Clin Oncol. April 11, 2022)
Sorry, the comment form is closed at this time.